JP7047236B2 - 微粒子化トルカポンを含む徐放性錠剤 - Google Patents

微粒子化トルカポンを含む徐放性錠剤 Download PDF

Info

Publication number
JP7047236B2
JP7047236B2 JP2019526375A JP2019526375A JP7047236B2 JP 7047236 B2 JP7047236 B2 JP 7047236B2 JP 2019526375 A JP2019526375 A JP 2019526375A JP 2019526375 A JP2019526375 A JP 2019526375A JP 7047236 B2 JP7047236 B2 JP 7047236B2
Authority
JP
Japan
Prior art keywords
tolcapone
tablet according
weight
cellulose
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019526375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523305A (ja
JP2019523305A5 (enExample
Inventor
リカル，アンナ ナルディ
ネグレ，ホセプ マリア スネ
ボラニョ，ヌリア レイッチ
ボロナ，ラウル インサ
ガムビン，オスカル ウエルタス
グラス，サンティアゴ エステバ
モール，ガル．ラ ペリコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Som Innovation Biotech SA
Original Assignee
Som Innovation Biotech SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Som Innovation Biotech SA filed Critical Som Innovation Biotech SA
Publication of JP2019523305A publication Critical patent/JP2019523305A/ja
Publication of JP2019523305A5 publication Critical patent/JP2019523305A5/ja
Application granted granted Critical
Publication of JP7047236B2 publication Critical patent/JP7047236B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019526375A 2016-07-29 2017-07-28 微粒子化トルカポンを含む徐放性錠剤 Active JP7047236B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7 2016-07-29
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (3)

Publication Number Publication Date
JP2019523305A JP2019523305A (ja) 2019-08-22
JP2019523305A5 JP2019523305A5 (enExample) 2020-08-13
JP7047236B2 true JP7047236B2 (ja) 2022-04-05

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526375A Active JP7047236B2 (ja) 2016-07-29 2017-07-28 微粒子化トルカポンを含む徐放性錠剤

Country Status (12)

Country Link
US (2) US11883538B2 (enExample)
EP (2) EP3275433A1 (enExample)
JP (1) JP7047236B2 (enExample)
KR (1) KR102484678B1 (enExample)
CN (1) CN109789100A (enExample)
AU (1) AU2017303333B2 (enExample)
DK (1) DK3490535T3 (enExample)
ES (1) ES2891355T3 (enExample)
MX (1) MX391116B (enExample)
PT (1) PT3490535T (enExample)
RU (1) RU2750670C2 (enExample)
WO (1) WO2018019997A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
JP2014530842A (ja) 2011-10-24 2014-11-20 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
DE69733752T2 (de) 1996-05-20 2006-06-01 G.D. Searle Llc, Chicago Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz
WO1999052504A1 (en) * 1998-04-09 1999-10-21 F. Hoffmann-La Roche Ag Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510320C (en) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Coated particles for sustained-release pharmaceutical administration
EP2335696A1 (en) * 2005-06-08 2011-06-22 Orion Corporation An entacapone-containing oral dosage form
SI2640358T1 (en) * 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
MX355309B (es) 2011-03-14 2018-04-16 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno.
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CN105209029A (zh) * 2013-03-13 2015-12-30 纽罗德姆有限公司 帕金森病的治疗方法
ES2957768T3 (es) * 2013-11-05 2024-01-25 Synagile Corp Suministro continuo de fármacos a través de la boca
CA3175785A1 (en) * 2014-09-04 2016-03-10 Intrance International Ab Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087882A1 (ja) 2007-01-15 2008-07-24 Kissei Pharmaceutical Co., Ltd. 胃内滞留型レボドパ徐放性製剤
JP2014530842A (ja) 2011-10-24 2014-11-20 ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． トランスサイレチン関連アミロイドーシスの新規療法

Also Published As

Publication number Publication date
RU2019103647A (ru) 2020-08-28
KR102484678B1 (ko) 2023-01-03
US20190167596A1 (en) 2019-06-06
MX391116B (es) 2025-03-21
EP3275433A1 (en) 2018-01-31
EP3490535A1 (en) 2019-06-05
KR20190034563A (ko) 2019-04-02
US11883538B2 (en) 2024-01-30
AU2017303333B2 (en) 2023-03-30
JP2019523305A (ja) 2019-08-22
RU2019103647A3 (enExample) 2020-10-12
US20240216282A1 (en) 2024-07-04
EP3490535B1 (en) 2021-07-14
MX2019001190A (es) 2019-09-06
AU2017303333A1 (en) 2019-03-14
PT3490535T (pt) 2021-09-30
CA3032211A1 (en) 2018-02-01
US12220487B2 (en) 2025-02-11
DK3490535T3 (da) 2021-10-04
WO2018019997A1 (en) 2018-02-01
BR112019001826A2 (pt) 2019-05-07
ES2891355T3 (es) 2022-01-27
CN109789100A (zh) 2019-05-21
RU2750670C2 (ru) 2021-06-30

Similar Documents

Publication Publication Date Title
KR101631140B1 (ko) 지속 방출형 경구용 아세트아미노펜/트라마돌 제형
JP2016531912A (ja) 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
CN104398481A (zh) 比拉斯汀口崩片及其制备方法
EP3711763A1 (en) Controlled release formulation
HK1208130A1 (en) Extended-release levetiracetam and method of preparation
US12220487B2 (en) Sustained release compositions comprising micronized tolcapone
DK2344140T3 (en) Process for the preparation of bioadhesive compact matrices
JP6002869B1 (ja) ジエノゲスト含有錠剤
EP4058025A1 (en) Pharmaceutical compositions comprising ticagrelor
WO2009008004A2 (en) Sustained release formulations of divalproex sodium
JP3007387B2 (ja) 徐放性製剤用基剤粉末
CA3032211C (en) Sustained release composition comprising micronized tolcapone
JPH02282322A (ja) 有効物質の浸食制御による放出システムおよびその製造方法
JP7547723B2 (ja) アビラテロン酢酸エステル含有製剤
BR112019001826B1 (pt) Composição de liberação prolongada compreendendo tolcapone micronizada
JP2017075138A (ja) ジエノゲスト含有錠剤
EP3525762A1 (en) Pharmaceutical composition comprising prasugrel besylate
HK40008562A (en) Sustained release composition comprising micronized tolcapone
WO2018208242A1 (en) Formulation of deferasirox tablet for oral suspension composition with better processability
BR102022001244A2 (pt) Composição farmacêutica de liberação modificada de ácido tranexâmico e comprimido de camada dupla
WO2022210829A1 (ja) アビラテロン酢酸エステル含有錠剤
BR112021004047A2 (pt) nova composição farmacêutica de lapatinib e processo para preparar uma nova composição farmacêutica de lapatinib
JP2019189642A (ja) 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物
GB2491205A (en) Composition comprising bosentan and diluents
CN101252919A (zh) 具有改良溶解曲线的药片

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220303

R150 Certificate of patent or registration of utility model

Ref document number: 7047236

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250